Lutz Korschgen

Lutz Korschgen

Auto-generated profile, based on publicly available information

Lutz Korschgen

Institute of Transplantation Diagnostics and Cell Therapeutics José Carreras Stem Cell Bank University Clinic Heinrich‐Heine‐University Düsseldorf Düsseldorf Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2020 in Vox Sanguinis
Verified
Journal Article
Open access
PDF file
SLStefanie Liedtke
Stefanie Liedtke
LKLutz Korschgen
Lutz Korschgen
JKJanine Korn
Janine Korn
ADAlmuth Duppers
Almuth Duppers
GKGesine Kogler
Gesine Kogler
Background: Based on a synergistic consortium, the cord blood (CB) bank Düsseldorf was responsible for the selection of HLA‐homozygous (HLA‐h) donors, contacting/re‐consenting the mothers, Good Manufacturing Practice (GMP)‐grade CD34+ enrichment, followed by short‐term expansion of CD34+ cells and qualification of the resulting CD34+ population as advanced therapy medicinal product (ATMP)‐starting material. Among 20 639 licensed Düsseldorf cord blood units (CBUs), 139 potential HLA‐h donors were identified with the most frequent 10 German haplotypes. 100% of the donors were contacted, and for 47·5%, consent was obtained. HLA‐A, ‐B, ‐C, ‐DR, ‐DQ and ‐DP were determined by sequencing.Methods: Thawing/washing of the CBUs was performed in the presence of Volulyte/HSA with Sepax®, CD34+ selection by automated CliniMACS®‐system (Miltenyi), expansion with qualified GMP‐grade cytokines and media in the GMP facility.Results: Here, we specify minimal criteria (≥5 x 105 viable CD34+‐count, ≥80% CD34+‐purity and ≥70% viability) and confirm that n = 10 CB units (max storage time 16 years) could be qualified for an ATMP starting material. The mean fold change expansion of isolated CD34+ cells at Day 3/4 (d3/4) was 3·38 ± 3·02 with a mean purity of 86·90 ± 10·38% and a high viability of 96·07 ± 4·72%.Conclusion: As of March 2019, approval was obtained by the Bezirksregierung Düsseldorf for the GMP‐compliant production. The production of HLA‐homozygous expanded CD34+ cells from cryopreserved CB under European ATMP regulations presented here describes the successful clinical translation and implementation of a qualified manufacturing process. This approach considers the main obstacle of rejection of transplanted cells (due to the immunological HLA barrier) by preselection of HLA‐homozygous transplants.